SCHEMBL21597604

SCHEMBL21597604

CC(C)(C)OC(=O)NC1CCc2sc(NC(=O)C3CC3)c(C(=O)OCC3CC3)c2C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
KDM4E B2RXH2 3/20 0.47
HSD17B10 Q99714 2/20 0.47
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 7/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 2/20 0.39
MAPK1 P28482 1/20 0.39
FLT3 P36888 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CNR2 P34972 2/20 0.38
CNR1 P21554 1/20 0.38
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603737 0.91 KMT2A (0.52) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21597633 0.88 KDM4E (0.60) MAPTKDM4EHSD17B10ALDH1A1GAA
SCHEMBL28607646 0.88 KDM4E (0.60) MAPTKDM4EHSD17B10ALDH1A1GAA
SCHEMBL21603936 0.87 MAPT (0.46) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21597712 0.85 KDM4E (0.47) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21597616 0.85 KDM4E (0.47) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21603941 0.85 CNR2 (0.46) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21603928 0.85 CNR2 (0.46) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL28609323 0.85 CNR2 (0.46) MAPTKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL21597233 0.84 ALDH1A1 (0.44) MAPTKDM4EHSD17B10KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885KDM4E 3965/4885HSD17B10 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.